Therapy ofClostridium difficileinfection: perspectives on a changing paradigm

Introduction: Clostridium difficile disease (CDI) have increased in frequency and severity over the past decade and are a leading cause of hospital acquired infections, contributing to increased hospital length of stay and costs, as well as associated increased mortality, especially amongst the elderly. Standard therapy has been associated with 20 – 30% relapse rates. Consequently, new CDI therapeutic approaches have emerged.